Current Research Studies
Cancer - PLAT-01: A Phase I Feasibility and Safety Study of Cellular Immunotherapy for Relapsed/Refractory Pediatric CD19+ Acute Lymphoblastic Leukemia Using Autologous T-cells Lentivirally Transduced to Express a CD19-Specific Chimeric Antigen Receptor
Condition or Therapy:
B cell Leukemia
What is the goal of this study?
The goal of this study is to understand how the personal body can use its own T cells to recognize CD19, a protein that is present on cancer cells.
Who can join the study?
This study may be a good fit for children and young adults who:
- Are 1 to 26 years old and
- Have CD19+ leukemia in a relapse
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106.